{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:50:59Z","timestamp":1778655059535,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019702","name":"Tokyo Metropolitan Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["KAKENHI 17K09523 and 21K08109"],"award-info":[{"award-number":["KAKENHI 17K09523 and 21K08109"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009665","name":"Vehicle Racing Commemorative Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00228-024-03745-y","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T06:50:49Z","timestamp":1724395849000},"page":"1795-1805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet\u2013cold pattern"],"prefix":"10.1007","volume":"80","author":[{"given":"Kenichi","family":"Matsushita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamichi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nagatomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morimasa","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"issue":"9624","key":"3745_CR1","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/s0140-6736(08)60695-9","volume":"371","author":"G Decaux","year":"2008","unstructured":"Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371(9624):1624\u20131632. https:\/\/doi.org\/10.1016\/s0140-6736(08)60695-9","journal-title":"Lancet"},{"issue":"12","key":"3745_CR2","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297(12):1332\u20131343. https:\/\/doi.org\/10.1001\/jama.297.12.1332","journal-title":"JAMA"},{"issue":"12","key":"3745_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319\u20131331. https:\/\/doi.org\/10.1001\/jama.297.12.1319","journal-title":"JAMA"},{"issue":"6","key":"3745_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10741-015-9503-x","volume":"20","author":"B Xiong","year":"2015","unstructured":"Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J, Rong S, Deng S, Cao Y, Zou Y, Huang J (2015) The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev 20(6):633\u2013642. https:\/\/doi.org\/10.1007\/s10741-015-9503-x","journal-title":"Heart Fail Rev"},{"issue":"10","key":"3745_CR5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/S0735-1097(03)00309-7","volume":"41","author":"A Nohria","year":"2003","unstructured":"Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW (2003) Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41(10):1797\u20131804","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"3745_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"18","key":"3745_CR7","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/cir.0000000000001063","journal-title":"Circulation"},{"issue":"2","key":"3745_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1253\/circj.CJ-11-1441","volume":"76","author":"SS Thomas","year":"2012","unstructured":"Thomas SS, Nohria A (2012) Hemodynamic classifications of acute heart failure and their clinical application: - an update. Circ J 76(2):278\u2013286","journal-title":"Circ J"},{"issue":"2","key":"3745_CR9","doi-asserted-by":"publisher","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290(2):F273-278. https:\/\/doi.org\/10.1152\/ajprenal.00195.2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"3745_CR10","first-page":"185","volume-title":"Heart failure : Pharmacologic Management","author":"O Hedrich","year":"2006","unstructured":"Hedrich O, Konstam MA, Udelson JE (2006) The role of vasopressin and vasopressin antagonists in heart failure. In: Feldman AM (ed) Heart failure\u202f: Pharmacologic Management. Blackwell Pub, pp 185\u2013202"},{"issue":"6","key":"3745_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/eurheartj\/ehi145","volume":"26","author":"P Sanghi","year":"2005","unstructured":"Sanghi P, Uretsky BF, Schwarz ER (2005) Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J 26(6):538\u2013543. https:\/\/doi.org\/10.1093\/eurheartj\/ehi145","journal-title":"Eur Heart J"},{"issue":"2","key":"3745_CR12","first-page":"175","volume":"23","author":"E Sears","year":"2010","unstructured":"Sears E, Brooks S (2010) New drugs approved in 2009. Proc (Bayl Univ Med Cent) 23(2):175\u2013183","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"10 Suppl 1","key":"3745_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","volume":"126","author":"JG Verbalis","year":"2013","unstructured":"Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ (2013) Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 126(10 Suppl 1):S1-42. https:\/\/doi.org\/10.1016\/j.amjmed.2013.07.006","journal-title":"Am J Med"},{"issue":"1","key":"3745_CR14","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1097\/mjt.0000000000000146","volume":"23","author":"M Kanaya","year":"2016","unstructured":"Kanaya M, Matsushita K, Inami T, Yamasaki S, Mizumi S, Minamishima T, Goda A, Ueda A, Sakata K, Satoh T, Yoshino H (2016) Successful Treatment of Severe Right-Sided Heart Failure Due to Postoperative Constrictive Pericarditis With Tolvaptan. Am J Ther 23(1):e264-267. https:\/\/doi.org\/10.1097\/mjt.0000000000000146","journal-title":"Am J Ther"},{"issue":"1","key":"3745_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12902-016-0104-z","volume":"16","author":"C Jamookeeah","year":"2016","unstructured":"Jamookeeah C, Robinson P, O\u2019Reilly K, Lundberg J, Gisby M, Landin M, Skov J, Trueman D (2016) Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocr Disord 16(1):22. https:\/\/doi.org\/10.1186\/s12902-016-0104-z","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"3745_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ehf2.12124","volume":"4","author":"A Pose","year":"2017","unstructured":"Pose A, Almenar L, Gavira JJ, Lopez-Granados A, Blasco T, Delgado J, Aramburu O, Rodriguez A, Manzano L, Manito N (2017) Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC project. ESC Heart Fail 4(2):130\u2013137. https:\/\/doi.org\/10.1002\/ehf2.12124","journal-title":"ESC Heart Fail"},{"issue":"3","key":"3745_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31(3):337\u2013348. https:\/\/doi.org\/10.1093\/ndt\/gfv456","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3745_CR18","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/asn.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE (2018) A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol 29(10):2458\u20132470. https:\/\/doi.org\/10.1681\/asn.2018060590","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3745_CR19","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.amjcard.2017.07.054","volume":"120","author":"K Matsushita","year":"2017","unstructured":"Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, Tanimoto S, Yagawa M, Shiraishi Y, Yoshino H, Yamamoto T, Nagao K, Takayama M (2017) Effect of Heart Failure Secondary to Ischemic Cardiomyopathy on Body Weight and Blood Pressure. Am J Cardiol 120(9):1589\u20131594. https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.054","journal-title":"Am J Cardiol"},{"issue":"3","key":"3745_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/hjh.0000000000001932","volume":"37","author":"K Matsushita","year":"2019","unstructured":"Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, Tanimoto S, Takei M, Hosoda T, Yamamoto Y, Shiraishi Y, Yoshino H, Yamamoto T, Nagao K, Takayama M (2019) Different prognostic associations of beta-blockers and diuretics in heart failure with preserved ejection fraction with versus without high blood pressure. J Hypertens 37(3):643\u2013649. https:\/\/doi.org\/10.1097\/hjh.0000000000001932","journal-title":"J Hypertens"},{"issue":"10","key":"3745_CR21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1111\/jgs.16050","volume":"67","author":"K Matsushita","year":"2019","unstructured":"Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, Yamamoto Y, Nagatomo Y, Yoshino H, Yamamoto T, Nagao K, Takayama M (2019) Younger- vs Older-Old Patients with Heart Failure with Preserved Ejection Fraction. J Am Geriatr Soc 67(10):2123\u20132128. https:\/\/doi.org\/10.1111\/jgs.16050","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"3745_CR22","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.numecd.2023.12.013","volume":"34","author":"K Matsushita","year":"2024","unstructured":"Matsushita K, Harada K, Kohno T, Nakano H, Kitano D, Matsuda J, Takei M, Yoshino H, Yamamoto T, Nagao K, Takayama M (2024) Prevalence and clinical characteristics of diabetic cardiomyopathy in patients with acute heart failure. Nutr Metab Cardiovasc Dis 34(5):1325\u20131333. https:\/\/doi.org\/10.1016\/j.numecd.2023.12.013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"3745_CR23","doi-asserted-by":"publisher","DOI":"10.23736\/s2724-5683.24.06510-4","author":"K Matsushita","year":"2024","unstructured":"Matsushita K, Harada K, Kohno T, Nakano H, Kitano D, Matsuda J, Yoshino H, Yamamoto T, Nagao K, Takayama M (2024) Comparison of clinical characteristics and prognostic factors in patients with heart failure with preserved ejection fraction with and without renal dysfunction. Minerva Cardiol Angiol. https:\/\/doi.org\/10.23736\/s2724-5683.24.06510-4","journal-title":"Minerva Cardiol Angiol"},{"issue":"6","key":"3745_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982\u2013992. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"key":"3745_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4419-1213-8","volume-title":"Observational studies","author":"PR Rosenbaum","year":"2010","unstructured":"Rosenbaum PR (2010) Sensitivity to hidden bias. In: Rosenbaum PR (ed) Observational studies, 2nd edn. Springer-Verlag, pp 105\u2013170","edition":"2"},{"issue":"12","key":"3745_CR26","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","volume":"97","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97(12):1759\u20131764. https:\/\/doi.org\/10.1016\/j.amjcard.2005.12.072","journal-title":"Am J Cardiol"},{"issue":"30","key":"3745_CR27","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.2174\/1381612822666160510125057","volume":"22","author":"K Matsushita","year":"2016","unstructured":"Matsushita K (2016) Pathogenetic pathways of cardiorenal syndrome and their possible therapeutic implications. Curr Pharm Des 22(30):4629\u20134637. https:\/\/doi.org\/10.2174\/1381612822666160510125057","journal-title":"Curr Pharm Des"},{"issue":"13","key":"3745_CR28","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/circulationaha.120.047643","volume":"142","author":"FR Mc Causland","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, Jhund PS, McGrath MM, Packer M, Shi V, Van Veldhuisen DJ, Zannad F, Comin-Colet J, Pfeffer MA, McMurray JJV, Solomon SD (2020) Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation 142(13):1236\u20131245. https:\/\/doi.org\/10.1161\/circulationaha.120.047643","journal-title":"Circulation"},{"issue":"5","key":"3745_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ehjcvp\/pvab030","volume":"7","author":"R Pontremoli","year":"2021","unstructured":"Pontremoli R, Borghi C, Perrone Filardi P (2021) Renal protection in chronic heart failure: focus on sacubitril\/valsartan. Eur Heart J Cardiovasc Pharmacother 7(5):445\u2013452. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab030","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"17","key":"3745_CR30","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, D\u00fcngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381(17):1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"issue":"11","key":"3745_CR31","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","volume":"69","author":"MA Konstam","year":"2017","unstructured":"Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE (2017) Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. J Am Coll Cardiol 69(11):1409\u20131419. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.035","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"3745_CR32","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291(16):1963\u20131971. https:\/\/doi.org\/10.1001\/jama.291.16.1963","journal-title":"JAMA"},{"issue":"11","key":"3745_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","volume":"69","author":"GM Felker","year":"2017","unstructured":"Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O\u2019Connor CM (2017) Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol 69(11):1399\u20131406. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.004","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3745_CR34","doi-asserted-by":"publisher","first-page":"886.e889","DOI":"10.1016\/j.jcrc.2014.05.023","volume":"29","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Ni H, Xu X (2014) Do the observational studies using propensity score analysis agree with randomized controlled trials in the area of sepsis? J Crit Care 29(5):886.e889\u2013815. https:\/\/doi.org\/10.1016\/j.jcrc.2014.05.023","journal-title":"J Crit Care"},{"issue":"9453","key":"3745_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/s0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM (2005) External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d Lancet 365(9453):82\u201393. https:\/\/doi.org\/10.1016\/s0140-6736(04)17670-8","journal-title":"Lancet"},{"issue":"7040","key":"3745_CR36","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","volume":"312","author":"N Black","year":"1996","unstructured":"Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312(7040):1215\u20131218","journal-title":"BMJ"},{"issue":"7205","key":"3745_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/bmj.319.7205.312","volume":"319","author":"M McKee","year":"1999","unstructured":"McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C (1999) Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 319(7205):312\u2013315","journal-title":"BMJ"},{"issue":"35\u201336","key":"3745_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3238\/arztebl.2016.0597","volume":"113","author":"O Kuss","year":"2016","unstructured":"Kuss O, Blettner M, Borgermann J (2016) Propensity Score: an Alternative Method of Analyzing Treatment Effects. Dtsch Arztebl Int 113(35\u201336):597\u2013603. https:\/\/doi.org\/10.3238\/arztebl.2016.0597","journal-title":"Dtsch Arztebl Int"},{"key":"3745_CR39","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516\u2013524. https:\/\/doi.org\/10.1080\/01621459.1984.10478078","journal-title":"J Am Stat Assoc"},{"issue":"19","key":"3745_CR40","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17(19):2265\u20132281","journal-title":"Stat Med"},{"key":"3745_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","volume":"2","author":"DB Rubin","year":"2001","unstructured":"Rubin DB (2001) Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2:169\u2013188","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"9262","key":"3745_CR42","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/s0140-6736(00)04257-4","volume":"357","author":"HD Aronow","year":"2001","unstructured":"Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS (2001) Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357(9262):1063\u20131068. https:\/\/doi.org\/10.1016\/s0140-6736(00)04257-4","journal-title":"Lancet"},{"issue":"12","key":"3745_CR43","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Husain A, Love TE, Gambassi G, Dell\u2019Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27(12):1431\u20131439. https:\/\/doi.org\/10.1093\/eurheartj\/ehi890","journal-title":"Eur Heart J"},{"issue":"3\u20134","key":"3745_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000047397","volume":"96","author":"DH Ellison","year":"2001","unstructured":"Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96(3\u20134):132\u2013143. https:\/\/doi.org\/10.1159\/000047397","journal-title":"Cardiology"},{"issue":"1","key":"3745_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1161\/circheartfailure.108.821785","volume":"2","author":"GM Felker","year":"2009","unstructured":"Felker GM, O\u2019Connor CM, Braunwald E (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2(1):56\u201362. https:\/\/doi.org\/10.1161\/circheartfailure.108.821785","journal-title":"Circ Heart Fail"},{"issue":"2","key":"3745_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R (2013) Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2013association between non-responders and chronic kidney disease. Circ J 77(2):397\u2013404","journal-title":"Circ J"},{"issue":"9","key":"3745_CR47","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1253\/circj.cj-14-0244","volume":"78","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I (2014) Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78(9):2240\u20132249. https:\/\/doi.org\/10.1253\/circj.cj-14-0244","journal-title":"Circ J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03745-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03745-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03745-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T06:05:42Z","timestamp":1728281142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03745-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3745"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03745-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"20 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. Ethics approval was granted by the Institutional Ethics Review Board of the Kyorin University School of Medicine, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Due to the retrospective nature of this study, the need for informed consent was waived by the Institutional Ethics Review Board of the Kyorin University School of Medicine, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Due to the retrospective nature of this study, the need for informed consent was waived by the Institutional Ethics Review Board of the Kyorin University School of Medicine, Japan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K. Harada, T. Miyamoto, K. Iida, Y. Yamamoto, Y. Shiraishi, Y. Nagatomo, H. Yoshino, and T. Yamamoto report receiving lecture fees from Otsuka Pharmaceutical Co., Ltd outside the submitted work. M. Takayama reports receiving lecture fees from Daiichi Sankyo Pharmaceutical Co. Ltd outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}